India Ranks 3rd Globally in Pharma Sector, Leads in Affordable Drugs
New Delhi | May 19, 2025 – India’s pharmaceutical industry is experiencing significant growth, reaffirming its status as a global leader. It ranks third in the world in terms of volume and fourteenth in value, contributing a remarkable 20% of the global medicine supply in 2023-24, with a turnover of ₹4,17,345 crore.
Experts anticipate a 7.8% growth in April 2025 alone, driven by strong global demand, new drug launches, and supportive government initiatives. Over the past five years, the sector has consistently experienced annual growth of over 10%.
“For the common man, this means more affordable medicines, better access to healthcare, and job opportunities across India—from laboratories in metropolitan areas to factories in small towns,” a government official stated.
India’s leadership is also highlighted in the vaccine sector, where it supplies:
– 55–60% of UNICEF’s vaccine needs
– 99% of WHO’s DPT vaccines
– 52% of global BCG vaccines
– 45% of measles vaccines
These vaccines not only protect millions worldwide but also create jobs and research opportunities for the youth in India.
Foreign investors are optimistic about India, investing ₹12,822 crore in 2023-24. With 100% Foreign Direct Investment (FDI) permitted in medical devices and greenfield pharmaceutical projects, India is becoming an attractive destination for global pharmaceutical companies.
The government’s proactive initiatives have played a significant role in supporting this growth, including:
– PMBJP: Over 15,479 Jan Aushadhi Kendras have been established, providing generic medicines that are up to 80% cheaper than branded alternatives.
Production – Linked Incentive (PLI) Schemes:
– ₹15,000 crore for manufacturing high-end drugs, including those for cancer and diabetes
– ₹6,940 crore to reduce dependency on imported raw materials like Penicillin G
– ₹3,420 crore to enhance domestic medical device production
– Bulk Drug Parks in Gujarat, Himachal Pradesh, and Andhra Pradesh under a ₹3,000 crore scheme
– SPI Scheme: ₹500 crore to strengthen research and laboratory infrastructure
Together, these initiatives ensure that medicines are made in India, for India and the world, at affordable prices and global quality standards.
